Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer

Terminated

• Conditions: Metaplastic Breast Carcinoma
• Interventions: Diagnostic Test: Vimentin/pan CK stain

• Registration Number: NCT04549584
• Lead Sponsor: Seoul National University Hospital

Brief Summary

prospective study for response of neoadjuvant chemotherapy in metaplastic carcinoma of triple negative breast cancer

Detailed Description

Vimentin/Pan CK staining will be performed on tissues of patient who visited Seoul National University Hospital and were diagnosed with triple negative breast cancer and decided to perform neoadjuvant chemotherapy under clinical judgement.

Histologically determined to be a metaplastic breast cancer or tested positive for vimentin/Pan CK patients decides as the metaplastic breast cancer. They evaluate the response rate of the neoadjuvant chemotherapy.

Patients with vimentin/Pan CK negative are diagnosed with non-metaplastic breast cancer and this group also confirms the response rate of neoadjuvant chemotherapy.

The group of metaplastic breast cancer will enroll 50 people, and the group of non-metaplastic breast cancer will enroll 100 people.

Study Timeline

• Status Verified: 2020-07
• Study First Submitted: 2020-07-30
• Study First Submitted QC: 2020-09-14
• Study First Posted: 2020-09-16
• Study Start: 2020-10-01
• Last Update Submitted: 2020-12-15
• Primary Completion: 2020-12-16
• Study Completion: 2020-12-16
• Last Update Posted: 2020-12-17

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

• over 20 years old
• patients with triple negative breast cancer diagnosed Seoul National University Hospital
• patients who decided to perform neoadjuvant chemotherapy under clinical judgement

Exclusion Criteria

• not applicable

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
metaplastic breast cancer	Vimentin/pan CK stain	Histologically determined to be a metaplastic breast cancer or tested positive for vimentin/Pan CK patients decides as the metaplastic breast cancer.

Primary Outcome Measures

Name	Time	Method
response rate of neoadjuvant chemotherapy	After neoadjuvant chemotherapy was finished. Average 6 month later.	response criteria for neoadjuvant chemotherapy-complete response (CR), partial response (PR), and no response (NR)

Trial Locations

Locations (1)

Seoul National University Hospital; 🇰🇷 Seoul, Jongno-gu, Korea, Republic of